메디젠피아

비상장계속사업자

MEDIZENPIA

정진오

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

메디젠피아

Business Reg. No. 6678800761 · CEO 정진오

I.Investment Overview

Target메디젠피아 (6678800761)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명메디젠피아
영문명MEDIZENPIA
대표자정진오
사업자등록번호6678800761
법인등록번호2841110179486
설립일2017.09.15

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW172021172022172023172024172025
영업이익100M KRW10.4202111.2202212.1202312.2202411.92025
순이익100M KRW3.62021220221.320232.320242.42025
Item20252024202320222021
자산총계271.7억원272.7억원273.4억원275.4억원276.9억원
부채총계238.5억원242억원245억원248.3억원251.8억원
자본총계33.2억원30.7억원28.4억원27.1억원25.1억원
매출액17억원17억원17억원17억원17억원
영업이익11.9억원12.2억원12.1억원11.2억원10.4억원
순이익2.4억원2.3억원1.3억원2억원3.6억원

VI.Financial Ratios

FY2025 basis

70.02%

영업이익률

14.31%

순이익률

0.9%

ROA

7.35%

ROE

718.91%

부채비율

12.21%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

메디젠피아 투심보고서 | Alpha Lenz